Skip to main content

Table 1 Patient Characteristics (Intent-To-Treat Population)

From: IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study

Parameter Engerix®-B HBsAg alone HBsAg + 3 μg IMP321 HBsAg + 10 μg IMP321 HBsAg + 30 μg IMP321 HBsAg + 100 μg IMP321
Number enrolled 8 8 9 9 8 8
Number completed 8 8 8 8 8 8
Age (years)a Mean ± SD 32.1 ± 11.2 41.0 ± 11.4 31.4 ± 8.0 29.0 ± 9.2* 37.3 ± 9.7 35.9 ± 7.4
Genderb       
   Male 7 7 9 9 8 8
   Female 1 1 0 0 0 0
Raceb       
   Caucasian 7 6 6 5 6 7
   Black 1 1 1 2 2 1
   Asian 0 0 1 1 0 0
   Other 0 1 1 1 0 0
  1. a Student's t-test. * p < 0.05 compared to HBsAg alone control group.
  2. b Chi-square. P >0.05 compared to HBsAg alone control group.
\